

**BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

**In the Matter of the Accusation** )  
**Against:** )  
)  
)  
**Andrew Michael Abarbanel, M.D.** )  
)  
**Physician's and Surgeon's** )  
**Certificate No. G 47490** )  
)  
**Respondent** )  
\_\_\_\_\_ )

**Case No. 800-2016-027720**

**DECISION**

**The attached Stipulated Surrender of License and Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.**


**This Decision shall become effective at 5:00 p.m. on November 8, 2019**

**IT IS SO ORDERED November 1, 2019**

**MEDICAL BOARD OF CALIFORNIA**

By: \_\_\_\_\_

**Christine J. Lally  
Deputy Director**



1 XAVIER BECERRA  
Attorney General of California  
2 MARY CAIN-SIMON  
Supervising Deputy Attorney General  
3 CAROLYNE EVANS  
Deputy Attorney General  
4 State Bar No. 289206  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3448  
6 Facsimile: (415) 703-5480  
*Attorneys for Complainant*

8 **BEFORE THE**  
9 **MEDICAL BOARD OF CALIFORNIA**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 800-2016-027720

13 **ANDREW MICHAEL ABARBANEL, M.D.**  
14 **3121 PARK AVE STE K**  
15 **SOQUEL, CA 95073-2956**

**STIPULATED SURRENDER OF  
LICENSE AND ORDER**

16 **Physician's and Surgeon's Certificate No. G**  
17 **47490**

Respondent.

18 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
19 entitled proceedings that the following matters are true:

20 **PARTIES**

21 1. Kimberly Kirchmeyer (Complainant) is the Executive Director of the Medical Board  
22 of California (Board). She brought this action solely in her official capacity and is represented in  
23 this matter by Xavier Becerra, Attorney General of the State of California, by Carlyne Evans,  
24 Deputy Attorney General.

25 2. ANDREW MICHAEL ABARBANEL, M.D. (Respondent) is represented in this  
26 proceeding by attorney Tom Still, whose address is: Hinshaw, Marsh, Still, and Hinshaw, LLP,  
27 12901 Saratoga Avenue, Saratoga, California 95070.  
28



1 Respondent hereby surrenders his Physician's and Surgeon's Certificate No. G 47490 for the  
2 Board's formal acceptance.

3 9. Respondent agrees that if he ever petitions for reinstatement of his Physician=s and  
4 Surgeon=s Certificate No. G 47490, all of the charges and allegations contained in Accusation  
5 No. 800-2016-027720 shall be deemed true, correct and fully admitted by Respondent for  
6 purposes of that reinstatement proceeding or any other licensing proceeding involving respondent.  
7 in the State of California.

8 10. Respondent understands that by signing this stipulation he enables the Board to issue  
9 an order accepting the surrender of his Physician's and Surgeon's Certificate without further  
10 process.

11 **CONTINGENCY**

12 11. This stipulation shall be subject to approval by the Board. Respondent understands  
13 and agrees that counsel for Complainant and the staff of the Board may communicate directly  
14 with the Board regarding this stipulation and surrender, without notice to or participation by  
15 Respondent or his counsel. By signing the stipulation, Respondent understands and agrees that he  
16 may not withdraw his agreement or seek to rescind the stipulation prior to the time the Board  
17 considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order,  
18 the Stipulated Surrender and Disciplinary Order shall be of no force or effect, except for this  
19 paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not  
20 be disqualified from further action by having considered this matter.

21 12. The parties understand and agree that Portable Document Format (PDF) and facsimile  
22 copies of this Stipulated Surrender of License and Order, including PDF and facsimile signatures  
23 thereto, shall have the same force and effect as the originals.

24 13. In consideration of the foregoing admissions and stipulations, the parties agree that  
25 the Board may, without further notice or formal proceeding, issue and enter the following Order:

26 ///

27 ///

28 ///

1 ORDER

2 IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. G 47490, issued  
3 to Respondent ANDREW MICHAEL ABARBANEL, M.D., is surrendered and accepted by the  
4 Board.

5 1. The surrender of Respondent's Physician's and Surgeon's Certificate and the  
6 acceptance of the surrendered license by the Board shall constitute the imposition of discipline  
7 against Respondent. This stipulation constitutes a record of the discipline and shall become a part  
8 of Respondent's license history with the Board.

9 2. Respondent shall lose all rights and privileges as a physician and surgeon in  
10 California as of the effective date of the Board's Decision and Order.

11 3. Respondent shall cause to be delivered to the Board his pocket license and, if one was  
12 issued, his wall certificate on or before the effective date of the Decision and Order.

13 4. If Respondent ever files an application for licensure or a petition for reinstatement in  
14 the State of California, the Board shall treat it as a petition for reinstatement. Respondent must  
15 comply with all the laws, regulations and procedures for reinstatement of a revoked or  
16 surrendered license in effect at the time the petition is filed, and all of the charges and allegations  
17 contained in Accusation No. 800-2016-027720 shall be deemed to be true, correct and admitted  
18 by Respondent when the Board determines whether to grant or deny the petition.

19  
20 ACCEPTANCE


21 I have carefully read the above Stipulated Surrender of License and Order and have fully  
22 discussed it with my attorney Tom Still. I understand the stipulation and the effect it will have on  
23 my Physician's and Surgeon's Certificate. I enter into this Stipulated Surrender of License and  
24 Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order  
25 of the Medical Board of California.

26  
27 DATED: 10-2-19

28 G. Abarbanel  
ANDREW MICHAEL ABARBANEL, M.D.  
Respondent


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

I have read and fully discussed with Respondent ANDREW MICHAEL ABARBANEL, M.D. the terms and conditions and other matters contained in this Stipulated Surrender of License and Order. I approve its form and content.

DATED: 10-14-19   
TOM STILL  
*Attorney for Respondent*

**ENDORSEMENT**

The foregoing Stipulated Surrender of License and Order is hereby respectfully submitted for consideration by the Medical Board of California of the Department of Consumer Affairs.

DATED: 10/28/2019 Respectfully submitted,  
XAVIER BECERRA  
Attorney General of California  
MARY CAIN-SIMON  
Supervising Deputy Attorney General  
  
for CAROLYNE EVANS  
Deputy Attorney General  
*Attorneys for Complainant*

**Exhibit A**

**Accusation No. 800-2016-027720**

1 XAVIER BECERRA  
Attorney General of California  
2 MARY CAIN-SIMON  
Supervising Deputy Attorney General  
3 CAROLYNE EVANS  
Deputy Attorney General  
4 State Bar No. 289206  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3448  
6 Facsimile: (415) 703-5480  
*Attorneys for Complainant*  
7

8 **BEFORE THE**  
9 **MEDICAL BOARD OF CALIFORNIA**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 800-2016-027720

13 **ANDREW MICHAEL ABARBANEL, M.D.**  
14 **4109 Countrywood Dr. SE**  
15 **Rochester, MN 55904-2730**

**ACCUSATION**

16 **Physician's and Surgeon's Certificate**  
17 **No. G 47490**

18 Respondent.

19  
20  
21 **PARTIES**

22 1. Kimberly Kirchmeyer (Complainant) brings this Accusation solely in her official  
23 capacity as the Executive Director of the Medical Board of California, Department of Consumer  
24 Affairs (Medical Board or Board).

25 2. On June 1, 1982, the Medical Board issued Physician's and Surgeon's Certificate  
26 Number G 47490 to Andrew Michael Abarbanel, M.D. (Respondent). The Physician's and  
27 Surgeon's Certificate was in full force and effect at all times relevant to the charges brought  
28 herein and will expire on September 30, 2019, unless renewed.



**JURISDICTION**

1  
2       3.     This Accusation is brought before the Board, under the authority of the following  
3 laws. All section references are to the Business and Professions Code (Code) unless otherwise  
4 indicated.

5       4.     Section 2227 of the Code provides that a licensee who is found guilty under the  
6 Medical Practice Act may have his or her license revoked, suspended for a period not to exceed  
7 one year, placed on probation and required to pay the costs of probation monitoring, or such other  
8 action taken in relation to discipline as the Board deems proper.

9       5.     Section 2234 of the Code states, in relevant part,  
10       “The board shall take action against any licensee who is charged with unprofessional  
11 conduct. In addition to other provisions of this article, unprofessional conduct includes, but is not  
12 limited to, the following:

13       “ . . . .”

14       “(b) Gross negligence.

15       “(c) Repeated negligent acts. To be repeated, there must be two or more negligent acts or  
16 omissions. An initial negligent act or omission followed by a separate and distinct departure from  
17 the applicable standard of care shall constitute repeated negligent acts.

18       “(1) An initial negligent diagnosis followed by an act or omission medically appropriate for  
19 that negligent diagnosis of the patient shall constitute a single negligent act.

20       “(2) When the standard of care requires a change in the diagnosis, act, or omission that  
21 constitutes the negligent act described in paragraph (1), including, but not limited to, a  
22 reevaluation of the diagnosis or a change in treatment, and the licensee’s conduct departs from the  
23 applicable standard of care, each departure constitutes a separate and distinct breach of the  
24 standard of care.

25       “(d) Incompetence.

26       “ . . . .”



1           10. Respondent noted that P-1 had been on an extremely low dose of Effexor<sup>2</sup> (37.5 mg)  
2 and that P-1 refused to raise the dosage because she had unsuccessfully attempted to increase it in  
3 the past. P-1 also refused to consider other antidepressants. P-1 told Respondent that she had  
4 taken Xanax<sup>3</sup> and Ativan,<sup>4</sup> 1.0 mg, and that she had been given Nuvigil<sup>5</sup> 250 mg as a sample and  
5 that it had helped her. Respondent did not pursue what benefits P-1 had obtained from these  
6 medications or under what circumstances she had received them, from whom, and over what  
7 period of time. Respondent wrote in his treatment plan that P-1 wanted to run the plan and that  
8 he would try to negotiate a change if needed. Because P-1 refused to change the dose or type of  
9 antidepressant, Respondent prescribed Nuvigil at the high dose of 250 mg she said she had  
10 received as a sample and Ativan 1 mg up to 2 or 3 mg. P-1 failed to tell Respondent that she had  
11 been getting Nuvigil 250 mg regularly from multiple providers at multiple pharmacies using two  
12 different home addresses dating back at least to January 2013. P-1 also failed to mention that she  
13 had been receiving various benzodiazepines from multiple pharmacies and providers. P-1  
14 continued getting Nuvigil and Ativan from other providers while Respondent was treating her and  
15 while he was prescribing the same medications. This was reflected on CURES reports that  
16 Respondent failed to access and review. Respondent did not discuss the risks and benefits of  
17 these medications and did not obtain informed consent from P-1 before prescribing them.

18  
19  
20 <sup>2</sup> Effexor, a trade name for venlafaxine, is an antidepressant belonging to a group of drugs  
21 called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs). It is a dangerous  
22 drug as defined in section 4022.

23 <sup>3</sup> Xanax, a trade name for alprazolam, is a benzodiazepine used for the management of  
24 anxiety disorders for the short-term relief of symptoms. It is a dangerous drug as defined in  
25 section 4022 and a Schedule IV controlled substance as defined in Health and Safety Code  
26 section 11057. Alprazolam is a central nervous system (CNS) depressant.

27 <sup>4</sup> Ativan, a trade name for lorazepam, is a benzodiazepine. It is a sedative used to treat  
28 anxiety. It is a dangerous drug as defined in section 4022 and a Schedule IV controlled substance  
as defined in Health and Safety Code section 11057. Since lorazepam has a central nervous  
system depressant effect, special care should be taken when prescribing lorazepam with other  
CNS depressant drugs.

<sup>5</sup> Nuvigil, a trade name for armodafinil, is a wakefulness-promoting agent. It reduces  
extreme sleepiness due to narcolepsy and other sleep disorders such as obstructive sleep apnea or  
shift work sleep disorder. Nuvigil tablets come in 50, 150, 200 or 250 mg of armodafinil.  
Armodafinil is a dangerous drug as defined in section 4022 of the Code and a Schedule IV  
controlled substance.

1 Respondent did not document a date for a return visit or establish a standard interval between  
2 visits. Only rarely throughout P-1's treatment did Respondent document a return date.

3 11. On P-1's second visit, March 8, 2015, Respondent took some additional history  
4 reflecting family discord. When Respondent asked if P-1 needed medication to treat her anxiety,  
5 she declined but asked for Ambien<sup>6</sup> 10 mg, which she said had helped in the past. P-1 mentioned  
6 that her back hurt but did not tell Respondent that she had been getting hydrocodone with  
7 acetaminophen<sup>7</sup> containing amounts of hydrocodone ranging from 5 mg to 10 mg from various  
8 providers at more than one pharmacy and, in the month prior to her seeing Respondent, tramadol<sup>8</sup>  
9 50 mg from three different providers and three different pharmacies. This was reflected on  
10 CURES reports, which Respondent could have reviewed but did not.

11 12. On April 3, 2015, P-1 reported that she had been "re-traumatized" when her nephew  
12 fell off a balcony, was seriously injured, and she had to provide his immediate treatment.  
13 Although P-1 told Respondent that she couldn't get the visual, the blood, everyone running  
14 around, out of her head, Respondent did not document a mental status exam or any inquiry about  
15 suicidality.

16 13. P-1 continued getting Nuvigil from multiple sources. On May 12, 2015, P-1 called  
17 for an early refill of Nuvigil and Ativan because she was on her way out of town. P-1 called  
18 again May 20, 2015 and reported that, while she was stabilizing, she had increased her Ativan on  
19 her own and wanted to have it prescribed 1 mg three times a day. Respondent called the

20 \_\_\_\_\_  
21 <sup>6</sup> Ambien, a trade name for zolpidem tartrate, is a sedative, also called a hypnotic. It is  
22 indicated for the short-term treatment of insomnia characterized by difficulties with sleep  
23 initiation. Dosage adjustment may be necessary when zolpidem tartrate is combined with other  
24 central nervous system depressant drugs because of the potentially additive effects. Zolpidem  
25 tartrate is a dangerous drug as defined in section 4022 and a Schedule IV controlled substance as  
26 defined in Health and Safety Code section 11057.

24 <sup>7</sup> Hydrocodone bitartrate w/APAP (hydrocodone with acetaminophen), also known by the  
25 trade name Norco among others, is a combination medication used to relieve moderate to severe  
26 pain. Hydrocodone is a semisynthetic narcotic analgesic and a dangerous drug as defined in  
27 section 4022 and, as of October 6, 2014, a Schedule II controlled substance. Prior to October  
28 2014, it had been a Schedule III controlled substance.

27 <sup>8</sup> Tramadol hydrochloride is a centrally acting opioid analgesic indicated for the  
28 management of moderate to moderately severe pain. It is a dangerous drug as defined in section  
4022 and a Schedule II controlled substance and narcotic as defined in section 11057 of the  
Health and Safety Code.

1 prescription in as requested by P-1. On June 17, 2015, P-1 called and said she wanted to start  
2 Lexapro<sup>9</sup> 10 mg because it had worked in the past. There are no chart notes reflecting  
3 Respondent having suggested that P-1 start Lexapro or P-1 having taken it. Although Respondent  
4 had not seen P-1 in two months, he called in the prescription. Respondent did not document the  
5 number of tablets he was prescribing, the manner in which the medication was to be taken, a  
6 discussion of side effects, or whether P-1 would be continuing to take the Effexor.

7 14. On June 19, 2015, Respondent noted that P-1's depression was getting worse but he  
8 did not document having inquired about suicidal ideation. Even though Respondent had initially  
9 prescribed Nuvigil for P-1's depression only because she had refused to change antidepressants or  
10 increase the dosage of Effexor and even though he had noted at that time that he would negotiate  
11 with her to change her antidepressant if the Nuvigil was not working, he had not assessed in  
12 subsequent visits how the Nuvigil was affecting her and, with her depression worsening and a  
13 new antidepressant, Lexapro, now having been added to her medications, he still did not assess  
14 her continued use of Nuvigil. And, although Respondent had increased P-1's Ativan at her  
15 request to three times a day because of increased anxiety, he did not assess whether Nuvigil was  
16 contributing to the anxiety.

17 15. On August 7, 2015, P-1 called Respondent complaining again of increased anxiety  
18 and asked for a refill of Ativan, which he called in. On August 13, 2015, P-1 said she was really  
19 depressed. P-1 declined an increase in the Lexapro saying that she had already tried to increase it  
20 and it made her jittery, so Respondent increased her Nuvigil prescription by 50 mg. He did not  
21 discuss her increasing anxiety and made no assessment of suicidal ideation. The August 27, 2015  
22 chart notes comprise two lines, primarily reflecting that P-1 asked for a note releasing her to go  
23 back to work. It's not clear whether this was an office visit or a phone call.

24 16. On September 8, 2015, Respondent noted that P-1 called "panicky." Respondent did  
25 not document a mental status exam or an inquiry about suicidality. P-1 asked for Lamictal<sup>10</sup> 200

26 <sup>9</sup> Lexapro, a trade name for escitalopram, is an antidepressant in a group of drugs called  
27 selective serotonin reuptake inhibitors (SSRIs). It is a dangerous drug as defined in section 4022.

28 <sup>10</sup> Lamictal, a trade name for lamotrigine, is an anticonvulsant or antiepileptic drug. It is  
used alone or with other medications to treat epileptic seizures in adults and children. Lamictal is

1 mg. Respondent wrote in parentheses that P-1 didn't tell him about the Lamictal. Respondent  
2 didn't chart having prescribed the Lamictal but it did become part of his treatment plan with  
3 Workers Compensation. Respondent did not document what purpose the Lamictal was prescribed  
4 for or how many tablets he prescribed and he never documented a discussion with P-1 about the  
5 purpose of the drug or the potential side effects. P-1 also asked for another prescription for  
6 Nuvigil, saying that she needed it because she had been breaking up the 250 mg tablets before he  
7 added the additional 50 mg. Respondent did not document the quantity of tablets prescribed or  
8 make it clear whether or not he called in the Nuvigil prescription.

9 17. On October 1, 2015, P-1 left a message seeking to refill Effexor 37.5 mg and  
10 Neurontin<sup>11</sup> 300 mg. Respondent wrote that he didn't have those down but that he would issue  
11 refills for them and then ask P-1 to update him regarding those refills. Respondent did not  
12 document the quantity of medications prescribed. On October 14, 2015, P-1 told Respondent that  
13 she was crying and very upset, apparently in response to her new job. Respondent wrote that P-1  
14 said that she had never had a panic attack before, implying that she was having one then. P-1 told  
15 Respondent that she had been taking one of the Ativan tablets every few days before she threw  
16 out 50 tablets and stopped taking them altogether three weeks before the visit. P-1 asked for  
17 Xanax. The chart notes say that they decided to leave her off benzodiazepines. The CURES  
18 report, however, reflects that P-1 filled a prescription from Respondent for 90 Ativan tablets two  
19 weeks before the visit, a week after she claims to have quit, and filled a prescription from  
20 Respondent for five Xanax tablets the day before the visit. There is no record that Respondent  
21 had prescribed that Xanax for P-1. Respondent did not document a mental status exam or an  
22 inquiry about suicidality.

23 18. On October 16, 2015, P-1 made an emergency visit asking for Xanax. P-1 said she  
24 had not been taking Ativan and Respondent wrote "maybe can use Klonopin 1 tid." P-1 reported

25 \_\_\_\_\_  
26 also used to delay mood episodes in adults with bipolar disorder. It is thought to work by  
27 restoring the balance of certain natural substances in the brain. Lamictal is a dangerous drug as  
28 defined in section 4022.

<sup>11</sup> Neurontin, a trade name for gabapentin, is a nerve pain medication and anticonvulsant.  
It is indicated for treatment of seizures and neuropathic pain caused by shingles. It is a CNS  
depressant. Gabapentin is a dangerous drug as defined in section 4022.

1 that she had doubled her Lexapro on her own and it had made her more anxious. P-1's heart was  
2 racing, chest heavy, and she had difficulty breathing. P-1 denied suicidal intent or ideation. P-1  
3 said she had not taken Ambien in months although she had filled a prescription from Respondent  
4 only two days before. Respondent gave P-1 a prescription for 30 Ambien tablets plus two refills  
5 and 21 Klonopin<sup>12</sup> tablets to be taken 3 times a day. Respondent did not address P-1's non-  
6 compliance with her medications. Respondent asked P-1 to follow up by telephone in two days.

7 19. P-1 followed up six days later when she called to say that she had not taken Nuvigil  
8 for a week or so and that she thought that might be the problem. Respondent had never assessed  
9 what if any benefit the Nuvigil was providing. In response to P-1's request and without  
10 discussing the possibility that Nuvigil might be contributing to P-1's anxiety, Respondent called  
11 in a prescription for Nuvigil.

12 20. On November 6, 2015, P-1 asked for a refill of Effexor and Respondent gave it to her  
13 without discussion. On December 18, 2015, Respondent billed Workers Compensation for a half  
14 hour visit that allegedly occurred on November 16, 2015 but did not prepare chart notes for a visit  
15 on that date. On December 18, 2015, P-1 reported that she had received bad news regarding her  
16 health but did not want to talk about it. Respondent did not document having explored this issue  
17 with P-1 and did not contact her primary care physician. Nor, despite the panic and anxiety P-1  
18 had been complaining about, did Respondent do an assessment of P-1's mental health. During  
19 the two-month period preceding this visit, CURES reports reflects that P-1 had received two

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 <sup>12</sup> Klonopin, a trade name for clonazepam, is an anticonvulsant of the benzodiazepine  
27 class of drugs. It is a dangerous drug as defined in section 4022 and a schedule IV controlled  
28 substance. It produces central nervous system depression and should be used with caution with  
other central nervous system depressant drugs.

1 prescriptions of hydrocodone, two of oxycodone,<sup>13</sup> three of buprenorphine<sup>14</sup>, two of  
2 phenobarbital,<sup>15</sup> and two of carisoprodol<sup>16</sup> from other physicians.

3 21. The chart notes do not reflect visits between December 18, 2015 and March 9, 2016.  
4 On January 20, 2016, the pharmacy called for Nuvigil and Effexor for P-1, which Respondent  
5 refilled. On March 7, 2016, P-1 called Respondent for Lamictal 200 mg. Respondent wrote that  
6 he "didn't seem to have recorded this regularly; not clear why not but will refill now."  
7 Respondent did not document the quantity of tablets prescribed. Respondent did not reassess why  
8 he had initially prescribed the Lamictal or document a discussion with P-1 about her experience  
9 with the Lamictal, its benefits, or any side effects.

10 22. On March 9, 2016, P-1 reported that she had trouble getting to sleep, that she had  
11 nightmares, that some days she couldn't get out of bed in the morning, that nearly half of her days  
12 were "bad," and that some days she didn't know if she could work if she were to find a job.  
13 Respondent discussed antidepressants, writing that they had tried Wellbutrin and it had given P-1  
14 three weeks of anxiety as had raising the dose of Effexor. Respondent had never documented a  
15 trial of Wellbutrin or that he had raised the dose of Effexor he was prescribing for P-1.  
16 Respondent did not mention doing a suicide assessment.

17 23. On P-1's next visit, April 14, 2016, she reported that her landlord had given her  
18 apartment to his nephew and she was living with friends and looking for a place to live.  
19 Respondent did not assess P-1's level of depression or do a suicide assessment. Respondent sent  
20

21  
22 <sup>13</sup> Oxycodone is a short-acting opioid whose principal therapeutic action is analgesia. It is  
23 a dangerous drug as defined in section 4022 and a schedule II controlled substance and narcotic  
as defined in section 11055 of the Health and Safety Code. It is a more potent pain reliever than  
morphine or hydrocodone.

24 <sup>14</sup> Buprenorphine is an opioid medication. It is a dangerous drug as defined in section  
25 4022 and a Schedule III controlled substance and narcotic as defined in section 11056 of the  
Health and Safety Code. Buprenorphine is used as a pain reliever and as part of drug addiction  
detoxification and maintenance programs.

26 <sup>15</sup> Phenobarbital is a barbiturate and nonselective central nervous system depressant which  
is primarily used as a sedative hypnotic and also as an anticonvulsant in subhypnotic doses. It is a  
27 dangerous drug as defined in section 4022 and a Schedule IV controlled substance.

28 <sup>16</sup> Carisoprodol, also known by the trade name Soma, is a muscle relaxant that blocks pain  
sensations between the nerves and the brain. It is a dangerous drug as defined in section 4022 and  
a Schedule IV controlled substance.



1 a letter to Workers Compensation saying that P-1 was totally disabled and needed to continue on  
2 medical leave.

3 24. P-1 called for a refill of Effexor on April 20, 2016, called for a refill of Nuvigil on  
4 April 25, 2016, and, "with increasing anxiety," called for Klonopin up to twice a day on May 16,  
5 2016. Respondent did not do a mental health assessment or assess P-1 for suicidality.  
6 Respondent did not document having prescribed the medications P-1 requested on these dates  
7 and, for the Effexor and the Klonopin, did not document quantities.

8 25. On May 26, 2016, P-1's psychotherapist called Respondent and told him of P-1's  
9 suicide. P-1 had hanged herself.

10 **FIRST CAUSE FOR DISCIPLINE**

11 **(Gross Negligence, Repeated Negligent Acts, and/or Failure to Maintain Adequate Records)**

12 26. Respondent is guilty of unprofessional conduct and subject to disciplinary action  
13 under section 2234, subdivision (b) and/or (c), and/or section 2266 of the Code in that  
14 Respondent was grossly negligent and/or committed repeated negligent acts and/or failed to  
15 maintain adequate medical records, including but not limited to the following:

16 A. Respondent failed to undertake an adequate assessment of Patient P-1 over the  
17 course of her treatment.

18 B. Respondent was unable to set limits on Patient P-1 and to remain in control of  
19 her treatment; he permitted her to direct her own treatment plan, failed to confront her non-  
20 compliance, failed to consult CURES or other providers despite P-1's request for various  
21 medications including a number of different benzodiazepines, and failed to direct the frequency  
22 of her treatment visits.

23 C. Respondent failed to, among other things, adequately diagnose Patient P-1  
24 before initiating treatment, to obtain informed consent, to monitor P-1's treatment, to monitor  
25 potential suicidality, to properly chart prescriptions for medications, to chart all visits clearly,  
26 and/or to document when the next appointment was scheduled.

27  
28

PATIENT P-2

1  
2       27. Patient P-2 was 58 years old when Respondent assumed his care on April 4, 2013. P-  
3 2 remained in Respondent's care until August 20, 2017 when he stopped returning Respondent's  
4 calls after the Medical Board contacted him about his treatment. At his initial visit, P-2  
5 complained of depression and feeling "down" for a long time, yet Respondent documented no  
6 history of his depressive feelings or prior treatment except to note that he had tried Zoloft.<sup>17</sup>  
7 There was no information about P-2's use of Zoloft. Although P-2 said that he thought about  
8 suicide, Respondent did not document any details about suicidal thoughts or history of suicidal  
9 thoughts or attempts and did not mention suicidality in any of P-2's subsequent visits.  
10 Respondent did not document inquiries about P-2's sleep, motivation, function at work or other  
11 activities of daily life. Respondent mentioned that P-2 said he used to drink a lot 25 years before  
12 but didn't offer any details and there was no discussion of any other substance abuse history.  
13 Respondent did not document whether or not P-2 had a family history of alcohol or substance  
14 abuse.

15       28. Respondent diagnosed P-2 with depression and social anxiety disorder although the  
16 only information documented about anxiety is from high school when, Respondent noted, P-2  
17 began to notice that it wasn't easy to get along with non-family members. Respondent did not  
18 document a discussion of P-2's current anxiety symptoms. Although Respondent noted under  
19 social history, "[n]o alcohol or other drugs," he documented that P-2 was taking Xanax he had  
20 gotten from a friend. Respondent wrote that P-2 was "[a] little too eager for high doses of  
21 Xanax," and then prescribed Xanax, 2 mg twice a day—noting that he was limiting P-2 to that  
22 amount—and 10 mg of Lexapro. Respondent did not describe the specific reason for prescribing  
23 Xanax and did not document the number of tablets or number of refills. Respondent did not  
24 document how much Xanax P-2 had been taking, or for how long, or whether P-2 had ever been  
25 prescribed benzodiazepines by a medical professional. Respondent noted that P-2 was

26  
27 <sup>17</sup> Zoloft, a trade name for sertraline, is an antidepressant in a group of drugs called  
28 selective serotonin reuptake inhibitors (SSRIs). It is primarily used to treat depression, obsessive-  
compulsive disorder, panic disorder, anxiety disorders, and PTSD. It is a dangerous drug as  
defined in section 4022.

1 “[p]robably also ADD [Attention Deficit Disorder]” but Respondent did not identify on what he  
2 based his ADD assessment. The only history Respondent documented regarding potential ADD  
3 is that P-2 had trouble with focus and concentration and a little hyperactivity. At the same time,  
4 Respondent described P-2 as having a “slow-moving demeanor.” Respondent did not document  
5 P-2’s current symptoms or childhood history of symptoms; his functioning at home, work, or  
6 school; behavioral disturbances; or other pertinent indications. Respondent did not question  
7 whether the symptoms that P-2 had described could have resulted from depression or anxiety.

8 29. Respondent documented that P-2 had chronic pain, obesity (“likely over 500 lbs”),  
9 and hypertension. Respondent noted that P-2 had tried Neurontin in connection with surgery, but  
10 not what the surgery was for, or when, or what the outcome of taking the Neurontin had been.  
11 Respondent listed an opiate-Tylenol medicine that P-2 was taking but did not identify it and did  
12 not discuss how long he had been taking it or if he had taken other opiate or benzodiazepine  
13 medications and did not check CURES or collaborate with other prescribers. In fact, Respondent  
14 did not check CURES once during the time he treated P-2. There is no documentation that  
15 Respondent discussed the risks and benefits of the medications he prescribed at the initial visit or  
16 their potential interactions with other medications, particularly benzodiazepines and opioids.  
17 Respondent did not document any blood pressure readings at this time or address any treatment P-  
18 2 was receiving for hypertension. Respondent did not consider pertinent negatives such as  
19 cardiac status before prescribing high doses of Xanax and, later, stimulant medication.  
20 Respondent documented an instruction to take “weekly vitals” but did not note any blood  
21 pressure readings until February 18, 2014 by which time P-2 had been on 60 mg of Adderall daily  
22 for 10 months. On February 18, 2014, Respondent prescribed Atenolol to P-2 for blood  
23 pressure.<sup>18</sup> P-2’s chart did not reflect that he was on Atenolol or any blood pressure medication  
24 up until then. P-2 told Respondent that his blood pressure was 130/80. The only subsequent  
25 mentions of blood pressure were in May 2014 and December 2016. Respondent did not take P-

26  
27 <sup>18</sup> Atenolol is a Beta-1-selective adrenergic antagonist, used to treat angina (chest pain)  
28 and high blood pressure. It is a dangerous drug as defined in section 4022.

1 2's blood pressure, consult with his primary care physician, or otherwise confirm his readings.  
2 Respondent never took or recorded P-2's pulse rate.

3 30. Two weeks after P-2's first visit, P-2 told Respondent that he didn't feel that 2 mg  
4 twice a day of Xanax was adequate and asked that it be doubled to 2 mg four times a day.  
5 Respondent wrote, "will compromise" and raised the amount to 2 mg three times a day. P-2 also  
6 said that he didn't want to continue on Lexapro and thought that a stimulant for the ADD might  
7 serve the same social function. While noting that "[w]e do have to worry that he's drug seeking,"  
8 Respondent said he had no reason to think so and prescribed Adderall<sup>19</sup> 10 mg up to three times a  
9 day, writing, "will follow carefully." Respondent prescribed Adderall without diagnosing P-2  
10 with ADD, without explaining how a stimulant would help social functioning in a person with  
11 social anxiety disorder, and without information about P-2's blood pressure or treatment of his  
12 hypertension.

13 31. On June 13, 2013, Respondent added half an Ambien tablet daily to P-2's regimen  
14 without any mention of sleep problems or giving a reason for prescribing the medication. A  
15 month later, Respondent increased the dosage to 1-1/2 tablets daily, again without explanation.  
16 On November 21, 2013, Respondent prescribed Valium<sup>20</sup> 10 mg daily to be taken at bedtime at P-  
17 2's request. P-2 wanted Valium because it was a longer-acting medication. Respondent did not  
18 express concern that P-2 knew that Valium was longer-acting or that he asked for a specific  
19 dosage. Respondent did not document his reason for acquiescing to P-2's request. On December  
20 28, 2013, P-2 asked for Ambien again. On January 30, 2014, Respondent noted, without  
21 discussion of the propriety of doing so, that P-2 alternated Valium and Ambien. Respondent  
22 simply acceded to this practice.

23  
24 <sup>19</sup> Adderall is a trade name for a combination of amphetamine and dextroamphetamine,  
25 central nervous system stimulants that affect chemicals in the brain and nerves that contribute to  
26 hyperactivity and impulse control. Adderall is used to treat attention deficit hyperactivity  
27 disorder (ADHD) and narcolepsy. Stimulants are known to have caused stroke, heart attack, and  
28 sudden death in people with high blood pressure, heart disease, or a heart defect. Adderall is a  
dangerous drug as defined in section 4022 and a Schedule II controlled substance as defined in  
section 11055 of the Health and Safety Code.

<sup>20</sup> Valium, a trade name for diazepam, is a benzodiazepine. It is a psychotropic drug used  
for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.  
It is a dangerous drug as defined in section 4022 and a Schedule IV controlled substance.

1           32. Although P-2's primary complaint at his first visit was depression and although he  
2 said he thought about suicide, Respondent did not mention depression or suicidal ideation in any  
3 of his chart notes thereafter.

4           33. On March 27, 2014, P-2 said he had been on Xanax four times a day for years and  
5 that three times a day "just doesn't do it." There was no record that P-2 had been on Xanax  
6 before starting treatment with Respondent other than what he got from a friend. Despite this and  
7 despite noting that P-2 had been "even keeled" and seemed to be doing well, Respondent  
8 increased the Xanax to 2 mg four times a day. Respondent did not consider the possibility that  
9 the stimulant Adderall may have been contributing to P-2's anxiety. On May 22, 2014,  
10 Respondent noted that P-2 was doing well, and without explanation, increased P-2's Adderall  
11 dose to 20 mg four times a day.

12           34. Respondent spent a number of visits attempting to negotiate lower doses of  
13 benzodiazepines with P-2. It appears that, although it isn't documented, P-2 had agreed at some  
14 point to stop taking Ambien. When the pharmacy called on October 9, 2014 for a refill of  
15 Ambien, Respondent called P-2 to remind him that that they had stopped the Ambien. P-2  
16 offered to go back on Ambien and stop Valium. Respondent said "fine" and prescribed Ambien.  
17 A month later, P-2 asked for just 30 Valium tablets and Respondent wrote "So #30" and  
18 prescribed the Valium.

19           35. In November 2015, Respondent congratulated P-2 for reducing his Xanax to three  
20 times a day. Four months later, Respondent's chart notes say that he is reducing Xanax to three  
21 times a day. Two months after that, Respondent increased the Xanax to four times a day at P-2's  
22 request in exchange for reducing Ambien from 15 mg to 10 mg a day, noting, "I fuss as usual"  
23 but he felt risk was worth getting stable. A few months later, with no discussion of why, P-2 was  
24 back up to 15 mg of Ambien daily.

25           36. On March 7, 2016, Respondent spoke to a pharmacist who told him that P-2 had been  
26 refilling his Adderall six days early for months, resulting in his getting an extra month's worth of  
27 Adderall. There is no documentation that Respondent discussed this with P-2.

28



1 difficulties could be adverse effects of the Adderall he prescribed; failed to document discussions  
2 of the risks and benefits of prescribed drugs and potential drug interactions; failed to document  
3 monitoring treatment with follow-up evaluation of P-2's response to treatment; and failed to  
4 monitor P-2's depression and potential suicidality.

5 D. Respondent was unable to set limits on Patient P-2 and to remain in control of  
6 his treatment and failed to consult CURES or other providers despite P-2's requests for specific  
7 medications including two benzodiazepines, a stimulant, and a hypnotic.

8 E. Respondent failed to recognize the cross-reactivity of Xanax, Valium, and  
9 Ambien and that tolerance and addiction to one can lead to tolerance and addiction to the others.

10 F. Respondent failed to chart all medications prescribed complete with dose,  
11 directions, quantity, and number of refills.

### 12 PATIENT P-3

13 40. Patient P-3 was 29 years old when Respondent assumed his care on January 10, 2012.  
14 He remained in Respondent's care until July 20, 2017. At his initial visit, P-3 complained of  
15 anxiety and hives.

16 41. Respondent documented that P-3 had weighed 345 pounds, undergone gastric bypass  
17 surgery, and lost 110 pounds. Respondent did not note when the surgery took place or what P-3's  
18 current weight was. Respondent did not document how long P-3 had suffered from anxiety, what  
19 P-3 had tried to do to treat it, or how anxiety affected P-3's life, other than that talking to people  
20 caused P-3 to get hives and that his hives kept him from working out. P-3 reported that he did not  
21 use alcohol or drugs but that marijuana helped him to focus. P-3 said that he had difficulty  
22 focusing, that he had anxiety from not getting "stuff" done, and could focus only on video games.  
23 P-3 said he spent all his time on the couch and slept only three hours per night. Except for  
24 recording that P-3 had undergone bypass surgery and had Bell's Palsy in the last year,  
25 Respondent did not document any past medical history and did not address P-3's bypass surgery,  
26 cardiac status, or blood pressure. The chart notes include no past psychiatric history or  
27 information about P-3's childhood or adult life, attention, concentration, executive functions, how  
28 he did in school, why he quit school, or past behavioral issues.

1           42. Respondent diagnosed P-3 with ADD, social anxiety disorder, mood disorder, quasi-  
2 addiction to video games, and anxiety disorder (questioning whether he had agoraphobia and/or  
3 generalized anxiety disorder). Respondent's plan was to prescribe Celexa<sup>21</sup> 20 mg to go to 40 mg  
4 and Adderall 10 mg to go to three times a day. Respondent did not document discussing other  
5 treatment options with P-3 such as psychotherapy, did not document informing P-3 that Adderall  
6 could make his anxiety and sleep problems worse, or obtain informed consent, and did not discuss  
7 how to monitor side effects in a post-gastric bypass patient who will be taking two medications.  
8 Respondent did not check P-3's blood pressure or cardiovascular status before prescribing the  
9 stimulant Adderall and did not document a plan to monitor his blood pressure. Respondent did  
10 not list the number of tablets prescribed or whether there were refills and gave P-3 a range of  
11 dosages of both medications without describing how he was to determine when to increase the  
12 dose. Respondent did not identify a date for a return visit. In fact, the next visit wasn't until  
13 seven months later.

14           43. The chart notes for the next visit on August 14, 2012 do not explain the seven-month  
15 hiatus. Respondent noted that P-3 had done well with Adderall 10 mg three times a day in the  
16 past without making clear whether he was referring to the period since his last visit or some prior  
17 time. Respondent did not document any information on how the Adderall had benefitted P-3,  
18 how it had affected his attention, concentration, executive functioning, or behavior or whether  
19 there were side effects. There was no mention of P-3's anxiety and no reference to Celexa.  
20 Respondent prescribed a one-month supply of Adderall 10 mg to be taken three times a day. No  
21 return date was documented.

22           44. P-3's next visit was four months later, December 6, 2012, again with no explanation  
23 for the hiatus. Respondent did not question whether P-3 was taking Adderall during the period he  
24 was not seeing him and, if he were, where he was getting it. Respondent did not check CURES to  
25 see if he had been getting it from other prescribers or document any attempt to consult with P-3's  
26 other providers. Because P-3 said that he felt doopy and slow when he ran out of Adderall, and

27           <sup>21</sup> Celexa, a trade name for citalopram, is an antidepressant in a group of drugs called  
28 selective serotonin reuptake inhibitors. It is primarily used to treat depression. It is a dangerous  
drug as defined in section 4022.



1 felt that his current dose was getting less effective and shorter acting, Respondent doubled the  
2 dose. Although P-3 complained of general anxiety around people and had earlier complained of  
3 sleeping only 3 hours a night, Respondent did not advise him of the possibility of increased  
4 anxiety from Adderall or of Adderall's effect on sleep. P-3 reported that his blood pressure was  
5 less than 120/70 when he remembered to check it but not did say how often he remembered to  
6 check it or when he had last checked it and did not provide specific numbers. Because P-3 said  
7 he had tried Celexa once—Respondent did not indicate that he recognized having prescribed it to  
8 P-3 himself—and it didn't seem to help with his anxiety around people, Respondent added two  
9 new drugs for anxiety, Luvox<sup>22</sup> 50 to 100 mg and Neurontin 300 mg. Respondent did not  
10 document having obtained informed consent or having addressed dosage titration. There is no  
11 further mention of Luvox in Respondent's chart notes for P-3 and there is no further mention of  
12 Neurontin until July 22, 2015 when P-3 reported that his aunt gave him Neurontin for a panic  
13 attack and Respondent then prescribed Neurontin 300 mg to be taken twice a day with the hope  
14 that they would be able to lower Adderall or Ativan. Ativan had not previously been documented  
15 as a drug P-3 was taking.

16 45. P-3's next visit was March 13, 2013, three months later. For the following 11  
17 months, there were entries approximately every two months that appear to reflect that P-3 or his  
18 wife had called in for or picked up prescriptions. The next entry that appears to be for an actual  
19 visit by P-3 is on February 18, 2014, following an 11-month hiatus.

20 46. On February 18, 2014, P-3 reported that he had raised his Adderall dose on his own to  
21 30 mg three times a day, an increase of 50%. P-3 said it calmed him but also reported increased  
22 anxiety and asked for Xanax 1 mg up to twice a day. Respondent adopted P-3's increased  
23 Adderall dosage and acceded to his request for Xanax without obtaining informed consent.  
24 Although Respondent told P-3 to take his blood pressure each time he filled a prescription for  
25 Adderall and report the number to him, there are no documented blood pressure readings for the

26 <sup>22</sup> Luvox, a trade name for fluvoxamine, is a selective serotonin reuptake inhibitor  
27 antidepressant. Luvox is used to treat social anxiety disorder (social phobia) or obsessive-  
28 compulsive disorders involving recurring thoughts or actions. Luvox inhibits the metabolism of  
caffeine and can contribute to anxiety and sleeplessness if caffeine is used while taking Luvox. It  
is a dangerous drug as defined in section 4022.

1 three plus years he continued to prescribe Adderall. Despite P-3's asking for a specific brand and  
2 dosage of benzodiazepine, Respondent did not ask P-3 about his experience with benzodiazepines  
3 or check CURES or consult with other providers to investigate his benzodiazepine use.

4 47. On November 6, 2014, Respondent added Lexapro 10 mg to P-3's regimen.

5 48. On March 26, 2015, Respondent documented that P-3 described having symptoms  
6 that sounded like Rapid Eye Movement (REM) intrusions. Respondent did not describe what the  
7 symptoms were or mention the possibility that they might be hallucinations and might relate to  
8 the dose of Adderall. There are no further references to REM intrusions in Respondent's  
9 subsequent chart notes for P-3.

10 49. On the March 26, 2015 visit, Respondent wrote that P-3 told him he hadn't taken  
11 Xanax for a month and that Respondent advised P-3 that he didn't want to give Xanax to him  
12 anymore. Two weeks later, P-3 came in specifically for Xanax, saying that he actually had been  
13 taking it, even though he had previously stated he had not been taking it.

14 50. Over time, there is deterioration in P-3's social relationships. Marital discord and  
15 separation are documented. On October 19, 2015, Respondent documented that P-3 had been  
16 written up at work for soliciting drugs.

17 51. On May 12, 2016, P-3 complained that the Adderall was "wearing off," so  
18 Respondent replaced one Adderall dose with Ritalin.<sup>23</sup> Respondent discontinued the Ritalin a  
19 month later noting that Adderall seemed better once again.

20 52. On June 13, 2016, P-3 reported that he was being singled out at work for criticism  
21 and was being monitored. P-3 said that he had always had issues with management, that they had  
22 told him he was not engaged enough, and it seemed they had decided he was not sociable and  
23 labelled him a drug addict. Despite this, Respondent did not discuss possible improper drug use  
24 with P-3 and did not check CURES or consult with his other providers.

25  
26 <sup>23</sup> Ritalin, a trade name for methylphenidate, is a central nervous system stimulant. It  
27 affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control.  
28 Ritalin is used to treat attention deficit disorder, attention deficit hyperactivity disorder, and  
narcolepsy. Ritalin is a dangerous drug as defined in section 4022 and a Schedule II controlled  
substance as defined in section 11055 of the Health and Safety Code.





1 up to 600 mg and Trileptal<sup>24</sup> 150 mg up to 450 mg. Respondent prescribed Neurontin throughout  
2 the entire time he treated P-4 and Trileptal through the end of 2016 or 2017. Respondent did not  
3 identify why he was prescribing either of these medications, although it may be inferred that the  
4 Neurontin was to treat anxiety. Respondent never explained the reason for prescribing Trileptal.  
5 Respondent did not document having discussed the potential risks and benefits of taking these  
6 medications at this initial visit or in any subsequent chart note even though Trileptal carries a risk  
7 of such serious side effects as electrolyte abnormalities and severe rash including Stevens  
8 Johnson Syndrome which has rare life-threatening potential.

9 59. At no point in his treatment of P-4 did Respondent document P-4's weight or vital  
10 signs. Although his initial notes are mostly illegible, it appears that he didn't discuss P-4's past  
11 psychiatric, childhood, social, family, medical, drug, or alcohol abuse history.<sup>25</sup> Respondent also  
12 failed to document discussions of these matters in subsequent notes and never conducted a mental  
13 status examination. Respondent did not document any contact with or even the name of P-4's  
14 primary care physician. Respondent never checked CURES.

15 60. On February 3, 2006, P-4 advised Respondent that he wanted to target ADD,  
16 learning and keeping focus. Respondent did not document anything beyond this to support a  
17 diagnosis of ADD. Respondent added dextroamphetamine,<sup>26</sup> one of the most powerful of the  
18 stimulants used to treat ADD, to P-4's medications at the high dose of 10 mg three times a day.  
19 Neither at this time nor at any subsequent visit did Respondent document informing P-4 that  
20 dextroamphetamine could make his anxiety worse or informing him of the risks and benefits of

21 <sup>24</sup> Trileptal, a trade name for oxcarbazepine, is an anticonvulsant or antiepileptic medicine.  
22 Trileptal is used either alone or with other medicines to treat partial seizures. It is also used off-  
23 label to treat some mood disorders such as bipolar disorder. It works by decreasing nerve  
impulses that cause seizures and pain. It is a dangerous drug as defined in section 4022.

24 <sup>25</sup> Respondent did make some reference to alcohol in his initial, mostly illegible chart  
notes; wrote "etoh+meds" in November 2007; and noted that P-4 had been a "crazy alcoholic"  
when he was 17 and that he was overdrinking in June 2009.

25 <sup>26</sup> Dextroamphetamine, also known by the trade names Dexedrine (short-acting) and  
26 Dexedrine Spansule (extended release), is a central nervous system stimulant. It affects  
chemicals in the brain and nerves that contribute to hyperactivity and impulse control.  
27 Dextroamphetamine is more powerful than most other medications used to treat narcolepsy and  
28 ADHD including Adderall, Ritalin, and Vyvanse. It is a dangerous drug as defined in section  
4022 and a Schedule II controlled substance as defined in section 11055 of the Health and Safety  
Code.

1 the drug. Respondent did not check P-4's blood pressure or cardiovascular status before  
2 prescribing the stimulant dextroamphetamine or at any subsequent time and did not document a  
3 plan to monitor his blood pressure. Respondent increased the dosage over the next months and  
4 years. By September 2008, P-4 was getting 90 mg of dextroamphetamine daily, 30 mg three  
5 times a day, and by January 2009, without explanation, Respondent increased Vyvanse<sup>27</sup> from 30  
6 mg to 90 mg daily. Respondent documented a Vyvanse dose of 70 mg a day in March 2009 and  
7 then never mentioned Vyvanse in P-4's chart notes again. In February 2011, with no explanation,  
8 Respondent increased the dosage of dextroamphetamine to 120 mg, 30 mg four times a day, the  
9 level at which it remained throughout the rest of the time he treated P-4.<sup>28</sup>

10 61. In January 2012, P-4 was having difficulty finding enough dextroamphetamine at  
11 pharmacies and Respondent switched him to Dexedrine Spansules<sup>29</sup> 30 mg four times a day and  
12 Adderall 30 mg four times a day in case P-4 couldn't get the Dexedrine Spansules. In May 2012,  
13 P-4 said he was feeling despair. The chart notes are mostly illegible but say that Respondent  
14 stopped Celexa because of sleep problems and that Respondent added a different antidepressant.  
15 P-4 was directed to return in one month but his next visit was four months later on September 18,  
16 2012. P-4 had failed to start the antidepressant, reduced the dose of Dexedrine because of fear of  
17 supply problems, and lost 35 pounds. Respondent did not discuss the lapse of time, P-4's  
18 decision to reduce his Dexedrine dosage on his own, or explore the reasons for the dramatic  
19 weight loss. Respondent gave P-4 a sample of a different antidepressant, Cymbalta,<sup>30</sup> and told  
20 him they should talk in two weeks. The next visit was six months later in March 2013 with no  
21 explanation for the hiatus. At that visit P-4 described losing it, breaking things, feeling isolated  
22 and cut off, being paranoid about the possibility of not getting Dexedrine, feeling more anxiety,

23 <sup>27</sup> Vyvanse, a trade name for lisdexamfetamine, is a central nervous system stimulant. It  
24 affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. It  
25 is FDA-approved to treat ADHD. Vyvanse is a dangerous drug as defined in section 4022 and a  
26 Schedule II controlled substance as defined in section 11055 of the Health and Safety Code.

27 <sup>28</sup> Respondent changed the dosing on July 9, 2012 to 60 mg two times a day instead of 30  
28 mg four times a day with no explanation.

<sup>29</sup> Dexedrine Spansule is a trade name for extended release dextroamphetamine, a central  
nervous system stimulant described in footnote 26, above.

<sup>30</sup> Cymbalta, a trade name for duloxetine, is a selective serotonin and norepinephrine  
reuptake inhibitor. It is used to treat depression and anxiety. Duloxetine is a dangerous drug as  
defined in section 4022.

1 feeling awful about himself when he was not taking the Dexedrine Spansules, and being in a  
2 downward spiral. P-4 said that everything was a project, even simple things like parking a car or  
3 ordering coffee. Respondent did not reassess his treatment of P-4, continuing to prescribe 120 mg  
4 of Dexedrine Spansules daily. Respondent did not consider whether Dexedrine tolerance,  
5 addiction, or amphetamine psychosis could be the cause of the deterioration. Respondent said  
6 that P-4 did not get the Cymbalta he prescribed at the last visit because P-4 would not do the  
7 paperwork. Respondent prescribed Luvox, the fourth antidepressant he prescribed for P-4, and  
8 directed P-4 to schedule monthly meetings with him. It appears from the chart notes that their  
9 next interaction was what Respondent described as an extended discussion about stress by  
10 telephone seven months later in conjunction with P-4's request for a note from Respondent for a  
11 one-month "stress leave." Respondent did not mention any details of P-4's stress or his response  
12 to treatment. P-4's next actual visit was a month after that. Respondent did not comment on the  
13 unexplained hiatus.

14         62. In November 2013, P-4 was still on stress leave and described paranoid feelings about  
15 being harassed at work saying that he got "absolutely stressed" just thinking about it. Respondent  
16 appeared to accept P-4's complaints at face value. By March 2014, P-4 was back at work and  
17 feeling very good about it, describing himself as one of the four people running the county. Two  
18 months later, however, P-4 was beginning to be upset with his job again and in September 2014,  
19 he told Respondent that "his work still sucked." In November 2014, P-4 described feeling really  
20 good and said that he expected a promotion soon but by May 2015, he was once again miserable  
21 and paranoid about work. P-4 did not get the promotion he wanted and blamed others, saying he  
22 had been "shafted," and that his co-workers had isolated him because he was so good at his job.  
23 Respondent's first note questioning the possible contribution of Dexedrine to P-4's anger and  
24 paranoia was on May 21, 2015. Respondent wrote that P-4 seemed to be having intrusions of  
25 issues that bothered him and questioned if he were having a depressive episode. Respondent  
26 queried whether Dexedrine were making P-4 more paranoid and asked him if he was more or less  
27 sensitive on Dexedrine. P-4 said he was not more sensitive and contended that he had not been  
28 angry since starting it nine years before. Respondent did not consider or document the possibility

1 that P-4's response might be a product of poor judgment and insight but took it at face value, left  
2 his medications as they were, and recommended another month of leave.

3 63. P-4's next visit was June 17, 2015. They discussed P-4's roommate's belief that P-4  
4 was bipolar. Respondent noted that he agreed with the diagnosis. Respondent did not document,  
5 and had not documented, a past history of bipolar symptoms, did not document a mental status  
6 exam to demonstrate manic presentation, never mentioned an assessment for suicidality or  
7 dangerousness with his anger and paranoia, and did not reassess his prescribing stimulants and  
8 antidepressants with the emergence of possible mania. P-4 said that he was a mess, agitated,  
9 depressed, and paranoid. Instead of modifying the stimulant, Respondent added lithium,  
10 Lithobid<sup>31</sup> 300 mg "after labs," advising him that he could go up to three times a day unless there  
11 were side effects. Respondent did not document advising P-4 of what the side effects might be or  
12 how P-4 should determine whether to increase his dose to more than once a day. Respondent did  
13 not discuss the symptoms of lithium toxicity, how to handle salt loss, potential interactions with  
14 NSAIDS or alcohol, or the need for routine monitoring of thyroid and renal function and lithium  
15 level. Although it appears that P-4 never had the laboratory tests done, Respondent continued to  
16 prescribe Lithobid for him throughout the rest of the time he treated him. Respondent never  
17 documented ordering or obtaining a lithium level or an assessment of P-4's thyroid function. In  
18 July 2015, P-4 described his return to work as a debacle stating that he was extremely frustrated  
19 and anxious, and that he couldn't stay there. Respondent recommended another two month leave  
20 of absence.

21 64. In September 2015, P-4 asked Respondent for a physician's certificate for leave but  
22 wanted him to avoid attributing his condition to work because he did not want to file a worker's  
23 compensation claim. Respondent gave P-4 a December 1, 2015 back to work date and noted that  
24 he needed to keep vigilant to make sure that P-4's responses were not paranoid and being made  
25 worse by stimulant medication. Despite these concerns and P-4's deterioration, Respondent did

26 <sup>31</sup> Lithobid is a trade name for lithium carbonate. Lithobid is indicated in the treatment of manic  
27 episodes of Bipolar Disorder and as a maintenance treatment for individuals with a diagnosis of  
28 Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes  
the intensity of those episodes, which may occur. It is a dangerous drug as defined in section  
4022.



1 not see P-4 again until March 2016, 7-1/2 months after his previous visit, and continued  
2 prescribing Dexedrine during this unexplained hiatus.

3 65. At the March 2016 visit, P-4 reported that after a bad report at work, he hid in his  
4 room and tried to kill himself by taking "a bunch of meds." Respondent also documented that P-  
5 4 had been drinking and that he had apparently stopped all his medications. It is not clear from  
6 the chart notes exactly when this happened. Despite the suicide attempt, Respondent did not  
7 investigate P-4's current suicidal ideation. Respondent received a report from a psychiatrist who  
8 had apparently assessed P-4 at the behest of his employer and put him on leave for two months,  
9 which described P-4 as being unfit for work, not attending meetings, raising his voice, and doing  
10 unsociable things. P-4 denied all of it and said that the workplace and union were corrupt.

11 66. The next entry is six weeks later on April 27, 2016, and it is not clear whether it  
12 reflects a visit or something else; it simply lists several "[s]tatements made that [P-4] says not  
13 true," that P-4 was rude; brushed people off when he came to work in July 2015; and that he was  
14 outside pacing around talking to himself. Respondent apparently met with P-4 and his roommate  
15 a few days later but made no notes. The next visit is nearly six and a half months later on  
16 November 14, 2016. P-4 was apparently back at work and complaining that he had been put in a  
17 basement and about disciplinary action, being placed on maximum suspension based on made-up  
18 information. P-4 said that he was appealing the suspension. Respondent did not comment on the  
19 lengthy period between visits and did not document any assessment of P-4 or evaluation of his  
20 treatment.

21 67. Eleven months passed before P-4's next visit, on November 12, 2017. Although P-4  
22 did not schedule a visit for 11 months, Respondent continued to prescribe for him. P-4 said that  
23 work was going well but that he was still not progressing with his social life. P-4 reported that he  
24 felt as if his highs and lows were smoothed by lithium. Respondent told him to return in two  
25 months.

26 68. Although there were several phone calls for prescriptions over the next several  
27 months, the next chart note that appears to reflect a visit with P-4 is five months later on March  
28

1 18, 2018. Respondent did not discuss P-4's failure to comply with his instruction to return in two  
2 months and did not reassess his treatment plan for P-4.

3 **FOURTH CAUSE FOR DISCIPLINE**

4 **(Gross Negligence, Repeated Negligent Acts, Excessive Prescribing, and/or Failure to  
5 Maintain Adequate Records)**

6 69. Respondent is guilty of unprofessional conduct and subject to disciplinary action  
7 under section 2234, subdivision (b) and/or (c), section 725, and/or section 2266 of the Code in  
8 that Respondent was grossly negligent and/or committed repeated negligent acts and/or  
9 prescribed excessive amounts of a controlled substance and/or failed to maintain adequate  
10 medical records, including but not limited to the following:

11 A. Respondent failed to undertake an adequate assessment of Patient P-4 over the  
12 course of his treatment.

13 B. Respondent prescribed and continued to prescribe a high dose of the very  
14 powerful stimulant dextroamphetamine throughout the time he treated Patient P-4 with very little  
15 evidence that he had attention deficit disorder; failed to consider or discuss with P-4 the  
16 possibility that his difficulty with anxiety may have resulted from his stimulant use; failed to  
17 document obtaining informed consent regarding side effects and addiction potential of  
18 dextroamphetamine; failed to obtain an adequate cardiac history for P-4 before prescribing  
19 dextroamphetamine and to monitor his blood pressure and pulse rate during his treatment with  
20 dextroamphetamine; and failed to collaborate with other providers or check CURES to monitor P-  
21 4's compliance

22 C. Respondent failed to document medical history to support his diagnoses of  
23 ADD and Bipolar Disorder for Patient P-4; failed to document his medical decision-making;  
24 failed to document a reason for prescribing Trileptal for P-4; failed to assess whether P-4's anger,  
25 anxiety, paranoia, and other symptoms could have been adverse effects of the dextroamphetamine  
26 Respondent prescribed; failed to document discussions of the risks and benefits of Lithobid and  
27 other prescribed drugs and potential drug interactions; failed to document monitoring treatment  
28

1 with follow-up evaluation of P-4's response to treatment; failed to ensure and monitor necessary  
2 laboratory testing when prescribing lithium for P-4; failed to monitor potential suicidality in a  
3 patient who was variably despondent, labile, angry, paranoid, and had made a suicide attempt.

4 D. Respondent was unable to set limits on Patient P-4 and to remain in control of  
5 his treatment, permitting him, among other things, to leave long periods between visits and  
6 decrease his dose of dextroamphetamine periodically on his own.

7  
8 **DISCIPLINARY CONSIDERATIONS**

9 70. To determine the degree of discipline, if any, to be imposed on Respondent Andrew  
10 Michael Abarbanel, M.D., Complainant alleges that on October 28, 2011, in a prior disciplinary  
11 action entitled In the Matter of the Accusation Against Andrew Abarbanel, M.D. before the  
12 Medical Board of California, in Case Number 03-2009-201966, Respondent's license was placed  
13 on probation for three years and Respondent was required to complete a number of educational  
14 requirements in resolution of allegations that, among other things, he prescribed controlled  
15 substances for patients without sufficient justification, failed to obtain informed consent from  
16 several patients for whom he was prescribing controlled substances, and failed to maintain  
17 adequate medical records. That decision is now final and is incorporated by reference as if fully  
18 set forth herein.

19  
20 **PRAYER**

21 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,  
22 and that following the hearing, the Medical Board of California issue a decision:

- 23 1. Revoking or suspending Physician's and Surgeon's Certificate Number G 47490,  
24 issued to Respondent;
- 25 2. Revoking, suspending or denying approval of Respondent's authority to supervise  
26 physician assistants and advanced practice nurses;
- 27 3. Ordering Respondent, if placed on probation, to pay the Board the costs of probation  
28 monitoring; and

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

4. Taking such other and further action as deemed necessary and proper.

DATED: September 26, 2019

  
\_\_\_\_\_  
KIMBERLY KIRCHMEYER  
Executive Director  
Medical Board of California  
Department of Consumer Affairs  
State of California  
*Complainant*